Angiotensin-Receptor Neprilysin Inhibitor for Heart Failure

An angiotensin-receptor neprilysin inhibitor (ARNI) combines sacubitril (a neprilysin inhibitor) with an angiotensin receptor blocker (ARB).17 Two major studies involving over 16,000 patients found LCZ696, an ARNI, efficacious in reducing death from CVD, as compared to enalapril in patients with heart failure. One of the trials was discontinued early, because the boundary for overwhelming benefit with LCZ696 had been crossed.18 The drug has been granted Fast Track status by the FDA and is expected to be available in 2015.

 


Continue Reading